Compare DexCom, Inc. (DXCM) vs Msci Inc (MSCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Msci Inc — how do they compare? DexCom, Inc. trades at $77.89 (market cap $28.06B), while Msci Inc trades at $630.6 (market cap $45.26B). The key difference: Msci Inc is the larger of the two by market cap, and Msci Inc pays a 1.32% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MSCI | |
|---|---|---|
Market Cap | $28.06B | $45.26B |
Sector | Health | Financials |
52-Week High | $89.53 | $643.83 |
52-Week Low | $54.84 | $511.84 |
Enterprise Value | $27.03B | $51.43B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MSCI trades at $626.59, up 2.48% today, with strong technical momentum as the stock approaches resistance at $628. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $4.55 versus $4.44, maintaining a three-quarter earnings beat streak. Recent strategic partnerships with UBS and the acquisition of First Street highlight growth initiatives in private markets and climate risk analytics. Valuation metrics show a P/E of 35.51 and P/S of 14.5, reflecting premium pricing for consistent performance.
The outlook remains positive with analyst consensus strongly bullish (73% buy ratings) and a price target of $718.14 offering 15% upside potential. Key risks include high debt levels at $4.51 billion and sensitivity to financial market conditions. The upcoming Q2 2026 earnings report on July 21, 2026, will be critical for validating growth trajectory amid elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →
